WO2005011592A3 - Substituted indazole-o-glucosides - Google Patents

Substituted indazole-o-glucosides Download PDF

Info

Publication number
WO2005011592A3
WO2005011592A3 PCT/US2004/024626 US2004024626W WO2005011592A3 WO 2005011592 A3 WO2005011592 A3 WO 2005011592A3 US 2004024626 W US2004024626 W US 2004024626W WO 2005011592 A3 WO2005011592 A3 WO 2005011592A3
Authority
WO
WIPO (PCT)
Prior art keywords
glucosides
substituted indazole
indazole
substituted
diabetes
Prior art date
Application number
PCT/US2004/024626
Other languages
French (fr)
Other versions
WO2005011592A2 (en
Inventor
Mona Patel
Philip Rybczynski
Maud Urbanski
Xiaoyan Zhang
Original Assignee
Janssen Pharmaceutica Nv
Tanabe Seiyaku Co
Mona Patel
Philip Rybczynski
Maud Urbanski
Xiaoyan Zhang
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv, Tanabe Seiyaku Co, Mona Patel, Philip Rybczynski, Maud Urbanski, Xiaoyan Zhang filed Critical Janssen Pharmaceutica Nv
Priority to YUP-2006/0320A priority Critical patent/RS20060320A/en
Priority to EP04779629A priority patent/EP1680414A4/en
Priority to CA002549017A priority patent/CA2549017A1/en
Priority to AU2004261264A priority patent/AU2004261264A1/en
Priority to EA200601555A priority patent/EA010655B1/en
Publication of WO2005011592A2 publication Critical patent/WO2005011592A2/en
Publication of WO2005011592A3 publication Critical patent/WO2005011592A3/en
Priority to IL175490A priority patent/IL175490A0/en
Priority to IS8443A priority patent/IS8443A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26Acyclic or carbocyclic radicals, substituted by hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Substituted indazole-O-glucosides, compositions containing them, and methods of using them, for example for the treatment of diabetes and Syndrome X are disclosed.
PCT/US2004/024626 2003-08-01 2004-07-29 Substituted indazole-o-glucosides WO2005011592A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
YUP-2006/0320A RS20060320A (en) 2003-08-01 2004-07-29 Substituted indazole-o-glucosides
EP04779629A EP1680414A4 (en) 2003-08-01 2004-07-29 Substituted indazole-o-glucosides
CA002549017A CA2549017A1 (en) 2003-08-01 2004-07-29 Substituted indazole-o-glucosides
AU2004261264A AU2004261264A1 (en) 2003-08-01 2004-07-29 Substituted indazole-O-glucosides
EA200601555A EA010655B1 (en) 2003-08-01 2004-07-29 Substituted indazole-o-glucosides
IL175490A IL175490A0 (en) 2003-08-01 2006-05-08 Substituted indazole-o-glucosides
IS8443A IS8443A (en) 2003-11-12 2006-05-09 Substituted indazole-o-glucoside

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US49153403P 2003-08-01 2003-08-01
US49152303P 2003-08-01 2003-08-01
US60/491,534 2003-08-01
US60/491,523 2003-08-01
US51938103P 2003-11-12 2003-11-12
US60/519,381 2003-11-12
US57972204P 2004-06-15 2004-06-15
US60/579,722 2004-06-15

Publications (2)

Publication Number Publication Date
WO2005011592A2 WO2005011592A2 (en) 2005-02-10
WO2005011592A3 true WO2005011592A3 (en) 2005-06-16

Family

ID=34120045

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/024626 WO2005011592A2 (en) 2003-08-01 2004-07-29 Substituted indazole-o-glucosides

Country Status (11)

Country Link
US (4) US7084124B2 (en)
EP (1) EP1680414A4 (en)
AR (1) AR048375A1 (en)
AU (1) AU2004261264A1 (en)
CA (1) CA2549017A1 (en)
CR (1) CR8402A (en)
EA (1) EA010655B1 (en)
IL (1) IL175490A0 (en)
RS (1) RS20060320A (en)
TW (1) TW200524950A (en)
WO (1) WO2005011592A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308204B2 (en) 2009-11-02 2016-04-12 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7202350B2 (en) * 2003-03-14 2007-04-10 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
CA2549017A1 (en) * 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides
US8785403B2 (en) 2003-08-01 2014-07-22 Mitsubishi Tanabe Pharma Corporation Glucopyranoside compound
AR045173A1 (en) * 2003-08-01 2005-10-19 Tanabe Seiyaku Co COMPOUNDS THAT HAVE INHIBITORY ACTIVITY AGAINST TRANSPORTER OF GLUCOSE DEPENDENT ON SODIUM
WO2006010557A1 (en) * 2004-07-27 2006-02-02 Boehringer Ingelheim International Gmbh D-glucopyranosyl phenyl-substituted cyclene, medicaments containing these compounds, their use, and method for the production thereof
MX2007003785A (en) * 2004-09-29 2007-07-12 Kissei Pharmaceutical 1-( ??-d-glycopyranosyl)-3-substituted nitrogenous heterocyclic compound, medicinal composition containing the same, and medicinal use thereof.
TW200637869A (en) 2005-01-28 2006-11-01 Chugai Pharmaceutical Co Ltd The spiroketal derivatives and the use as therapeutical agent for diabetes of the same
AR053329A1 (en) * 2005-01-31 2007-05-02 Tanabe Seiyaku Co INDOL DERIVATIVES USEFUL AS INHIBITORS OF GLUCOSE CONVEYORS DEPENDENT ON SODIUM (SGLT)
MY147375A (en) 2005-01-31 2012-11-30 Mitsubishi Tanabe Pharma Corp Indole derivatives
CA2597269A1 (en) 2005-02-15 2006-08-24 Kissei Pharmaceutical Co., Ltd. 1-substituted-7-(beta-d-glycopyranosyloxy)(aza)indole compound and pharmaceutical containing the same
US7772191B2 (en) 2005-05-10 2010-08-10 Boehringer Ingelheim International Gmbh Processes for preparing of glucopyranosyl-substituted benzyl-benzene derivatives and intermediates therein
TW200726755A (en) * 2005-07-07 2007-07-16 Astellas Pharma Inc A crystalline choline salt of an azulene derivative
JP2007063225A (en) * 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
EP1948614A2 (en) * 2005-11-18 2008-07-30 Takeda San Diego, Inc. Glucokinase activators
WO2007104034A2 (en) 2006-03-08 2007-09-13 Takeda San Diego, Inc. Glucokinase activators
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
ATE522518T1 (en) 2006-05-31 2011-09-15 Takeda San Diego Inc INDAZOLE AND ISOINDOLE DERIVATIVES AS GLUCOKINASE ACTIVATE SUBSTANCES
TWI432446B (en) * 2006-07-27 2014-04-01 Chugai Pharmaceutical Co Ltd Fused ring spiroketal derivative and use thereof as anti-diabetic drug
TWI418556B (en) * 2006-07-27 2013-12-11 Mitsubishi Tanabe Pharma Corp Indole derivatives
TWI499414B (en) 2006-09-29 2015-09-11 Lexicon Pharmaceuticals Inc Inhibitors of sodium glucose co-transporter 2 and methods of their use
US20080102137A1 (en) * 2006-10-31 2008-05-01 Guffey Manning V R Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization
US7666845B2 (en) * 2006-12-04 2010-02-23 Janssen Pharmaceutica N.V. Compounds having inhibitory activity against sodium-dependent glucose transporter
UY30730A1 (en) * 2006-12-04 2008-07-03 Mitsubishi Tanabe Pharma Corp CRYSTAL FORM OF HEMIHYDRATE 1- (B (BETA) -D-GLUCOPYRANOSIL) -4-METHYL-3- [5- (4-FLUOROPHENYL) -2-TIENYLMETHYL] BENZENE
JP5419706B2 (en) 2006-12-20 2014-02-19 タケダ カリフォルニア インコーポレイテッド Glucokinase activator
CA2673498C (en) * 2006-12-21 2012-04-24 Astellas Pharma Inc. Method for producing c-glycoside derivative and intermediate for synthesis thereof
WO2008077171A1 (en) * 2006-12-22 2008-07-03 Novelix Therapeutics Gmbh Treatment of diabetes by at least one epidermal growth factor receptor specific antibody or a derivative thereof
WO2008116107A2 (en) * 2007-03-21 2008-09-25 Takeda San Diego, Inc. Piperazine derivatives as glucokinase activators
HUE035130T2 (en) 2007-09-10 2018-05-02 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt
CL2008003653A1 (en) 2008-01-17 2010-03-05 Mitsubishi Tanabe Pharma Corp Use of a glucopyranosyl-derived sglt inhibitor and a selected dppiv inhibitor to treat diabetes; and pharmaceutical composition.
US9056850B2 (en) * 2008-10-17 2015-06-16 Janssen Pharmaceutica N.V. Process for the preparation of compounds useful as inhibitors of SGLT
US20110009347A1 (en) 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
JP5658751B2 (en) 2009-07-10 2015-01-28 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプJanssen Pharmaceutica Naamloze Vennootschap Crystallization method for 1- (β-D-glucopyranosyl) -4-methyl-3- [5- (4-fluorophenyl) -2-thienylmethyl] benzene
EP2478357A1 (en) * 2009-09-15 2012-07-25 Janssen Pharmaceutica, N.V. Use of alpha-methylglucoside (amg) as an indicator for glucose absorption and excretion
JP5758900B2 (en) 2009-09-30 2015-08-05 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Process for the preparation of glucopyranosyl-substituted benzylbenzene derivatives
DK2488515T3 (en) * 2009-10-14 2017-02-27 Janssen Pharmaceutica Nv PROCEDURE FOR THE PREPARATION OF COMPOUNDS USED AS INHIBITORS OF SGLT2
EP2491050A2 (en) 2009-10-20 2012-08-29 Novartis AG Glycoside derivative and uses thereof
US8163704B2 (en) 2009-10-20 2012-04-24 Novartis Ag Glycoside derivatives and uses thereof
MX339570B (en) 2010-05-11 2016-05-31 Janssen Pharmaceutica Nv Pharmaceutical formulations comprising 1 - (beta-d-glucopyranosyl ) - 2 -thienylmethylbenzene derivatives as inhibitors of sglt.
SI2697218T1 (en) 2011-04-13 2016-07-29 Janssen Pharmaceutica Nv Process for the preparation of compounds useful as inhibitors of sglt2
EP2697240B1 (en) 2011-04-14 2015-09-16 Novartis AG Glycoside derivatives and uses thereof
US8614195B2 (en) 2011-04-14 2013-12-24 Novartis Ag Glycoside derivatives and uses thereof
TWI542596B (en) 2011-05-09 2016-07-21 健生藥品公司 L-proline and citric acid co-crystals of (2s,3r,4r,5s,6r)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)tetrahydro-2h-pyran-3,4,5-triol
PT2981271T (en) 2013-04-05 2019-02-19 Boehringer Ingelheim Int Therapeutic uses of empagliflozin
US20140303097A1 (en) 2013-04-05 2014-10-09 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
CN113181161A (en) 2013-04-18 2021-07-30 勃林格殷格翰国际有限公司 Pharmaceutical compositions, methods of treatment and uses thereof
CR20170456A (en) 2015-04-07 2018-06-13 Intercept Pharmaceuticals Inc PHARMACEUTICAL COMPOSITIONS FOR COMBINED THERAPIES
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4584369A (en) * 1981-07-31 1986-04-22 Sloan-Kettering Institute For Cancer Research Anti-leukemic beta-glycosyl C-nucleosides
US5149838A (en) * 1991-09-20 1992-09-22 Merck & Co., Inc. Intermediates for substituted azetidinones useful as anti-inflammatory and antidegenerative agents
US5334225A (en) 1992-07-15 1994-08-02 Kao Corporation Keratinous fiber dye composition containing a 2-substituted amino-5-alkylphenol derivative coupler
US5731292A (en) * 1992-11-12 1998-03-24 Tanabe Seiyaku Co., Ltd. Dihydrochalcone derivatives which are hypoglycemic agents
CA2102591C (en) * 1992-11-12 2000-12-26 Kenji Tsujihara Hypoglycemic agent
US6297363B1 (en) 1993-02-12 2001-10-02 Nomura Co., Ltd. Glycoside indoles
US5830873A (en) * 1994-05-11 1998-11-03 Tanabe Seiyaku Co., Ltd. Propiophenone derivative and a process for preparing the same
US5780483A (en) * 1995-02-17 1998-07-14 Smithkline Beecham Corporation IL-8 receptor antagonists
JP3059088B2 (en) * 1995-11-07 2000-07-04 田辺製薬株式会社 Propiophenone derivatives and their production
DK0850948T3 (en) * 1996-12-26 2002-07-29 Tanabe Seiyaku Co Propiophenone derivatives and process for their preparation
US20020032164A1 (en) * 1998-12-30 2002-03-14 Dale Roderic M. K. Antimicrobial compounds and methods for their use
MXPA02002257A (en) 1999-08-31 2002-09-30 Maxia Pharmaceuticals Inc Benzylidene thiazolidinediones and analogues and their use in the treatment of diabetes.
US6515117B2 (en) * 1999-10-12 2003-02-04 Bristol-Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
PH12000002657B1 (en) 1999-10-12 2006-02-21 Bristol Myers Squibb Co C-aryl glucoside SGLT2 inhibitors
US6627611B2 (en) * 2000-02-02 2003-09-30 Kotobuki Pharmaceutical Co Ltd C-glycosides and preparation of thereof as antidiabetic agents
BR0109323A (en) 2000-03-17 2002-12-24 Kissei Pharmaceutical Derivatives of gluco piranosiloxi benzyl benzene, medicinal compositions containing the same and intermediates for the preparation of derivatives
US6555519B2 (en) 2000-03-30 2003-04-29 Bristol-Myers Squibb Company O-glucosylated benzamide SGLT2 inhibitors and method
US6683056B2 (en) 2000-03-30 2004-01-27 Bristol-Myers Squibb Company O-aryl glucoside SGLT2 inhibitors and method
US6936590B2 (en) * 2001-03-13 2005-08-30 Bristol Myers Squibb Company C-aryl glucoside SGLT2 inhibitors and method
AU2002307250B2 (en) 2001-04-10 2006-09-14 Agensys, Inc. Nucleic acid and corresponding protein entitled 121P2A3 useful in treatment and detection of cancer
CA2444481A1 (en) 2001-04-11 2002-10-24 Bristol-Myers Squibb Company Amino acid complexes of c-aryl glucosides for treatment of diabetes and method
EP1400529A4 (en) 2001-05-30 2007-12-19 Kissei Pharmaceutical Glucopyranosyloxypyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate therefor
JP4399254B2 (en) 2001-06-20 2010-01-13 キッセイ薬品工業株式会社 Nitrogen-containing heterocyclic derivative, pharmaceutical composition containing the same, pharmaceutical use thereof and production intermediate thereof
JPWO2003011880A1 (en) 2001-07-31 2004-11-18 キッセイ薬品工業株式会社 Glucopyranosyloxybenzylbenzene derivatives, pharmaceutical compositions containing the same, pharmaceutical uses thereof and intermediates for the production thereof
WO2003020737A1 (en) 2001-09-05 2003-03-13 Bristol-Myers Squibb Company O-pyrazole glucoside sglt2 inhibitors and method of use
US6617313B1 (en) * 2002-03-13 2003-09-09 Council Of Scientific And Industrial Research Glucopyranoside and process of isolation thereof from pterocarpus marsupium pharmaceutical composition containing the same and use thereof
US6562791B1 (en) * 2002-03-29 2003-05-13 Council Of Scientific And Industrial Research Glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
CN1280290C (en) 2002-04-08 2006-10-18 科学与工业研究委员会 Novel glucopyranoside, process for isolation thereof, pharmaceutical composition containing same and use thereof
US7202350B2 (en) 2003-03-14 2007-04-10 Astellas Pharma Inc. C-glycoside derivatives and salts thereof
JP2004300102A (en) 2003-03-31 2004-10-28 Kissei Pharmaceut Co Ltd Condensed heterocyclic derivative, pharmaceutical composition containing the same and its pharmaceutical application
CA2549017A1 (en) * 2003-08-01 2005-02-10 Mona Patel Substituted indazole-o-glucosides

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6153632A (en) * 1997-02-24 2000-11-28 Rieveley; Robert B. Method and composition for the treatment of diabetes
WO2001064669A1 (en) * 2000-03-03 2001-09-07 Pfizer Products Inc. Pyrazole ether derivatives as anti-inflammatory/analgesic agents

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9308204B2 (en) 2009-11-02 2016-04-12 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9439902B2 (en) 2009-11-02 2016-09-13 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
US9439901B2 (en) 2009-11-02 2016-09-13 Pfizer Inc. Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives

Also Published As

Publication number Publication date
AR048375A1 (en) 2006-04-26
EA200601555A1 (en) 2007-02-27
IL175490A0 (en) 2011-08-01
US20060217323A1 (en) 2006-09-28
US7511021B2 (en) 2009-03-31
RS20060320A (en) 2008-08-07
EA010655B1 (en) 2008-10-30
US7816331B2 (en) 2010-10-19
CR8402A (en) 2008-09-10
US20050032711A1 (en) 2005-02-10
US20100062971A1 (en) 2010-03-11
US20090099104A1 (en) 2009-04-16
EP1680414A2 (en) 2006-07-19
US7084124B2 (en) 2006-08-01
AU2004261264A1 (en) 2005-02-10
CA2549017A1 (en) 2005-02-10
EP1680414A4 (en) 2009-05-27
TW200524950A (en) 2005-08-01
WO2005011592A2 (en) 2005-02-10

Similar Documents

Publication Publication Date Title
WO2005011592A3 (en) Substituted indazole-o-glucosides
WO2005012243A3 (en) Substituted indole-o-glucosides
UA86042C2 (en) Substituted indazole-o-glucosides
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
WO2007133290A3 (en) Anti-ox40l antibodies and methods using same
AU2003262747A1 (en) Compounds, compositions, and methods
AU2003236527A1 (en) Compounds, compositions, and methods
AU2003265242A1 (en) Compounds, compositions, and methods
AU2003247798A1 (en) Nozzles and components thereof and methods for making the same
WO2006086562A3 (en) Phenylazetidinone derivatives
AU2003270015A1 (en) Compounds, compositions, and methods
WO2006083936A3 (en) Anti-ephb2 antibodies and methods using same
WO2003101397A3 (en) Tetravalent dengue vaccines
AU2003299612A1 (en) Compounds, compositions and methods
WO2005030129A3 (en) Quinoline potassium channel inhibitors
WO2005085188A3 (en) Compounds and methods for anti-tumor therapy
WO2005117543A3 (en) N-sulfonylcarboximidamide apoptosis promoters
WO2005037470A3 (en) Encapsulated nanoparticles, products containing the same, and methods for using the same
WO2004069160A3 (en) Chemical compounds
AU2003290507A1 (en) Compounds, compositions and methods
AU2003277079A1 (en) Compounds, compositions, and methods
EP1670894B8 (en) Compositions including different types of transfer factor, methods for making the compositions, and methods of treatment using the compositions
WO2005030792A3 (en) Quinoline potassium channel inhibitors
AU2003201163A1 (en) Method for the preparation of lariciresinol, cyclolariciresinol and secoisolariciresinol
AU2003241785A1 (en) Intravenous composition, process for producing the same and preparation thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 175490

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 547049

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004779629

Country of ref document: EP

Ref document number: P-2006/0320

Country of ref document: YU

Ref document number: CR2006-008402

Country of ref document: CR

WWE Wipo information: entry into national phase

Ref document number: 200603879

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2549017

Country of ref document: CA

Ref document number: 1596/KOLNP/2006

Country of ref document: IN

WWP Wipo information: published in national office

Ref document number: 2004779629

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2004261264

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200601555

Country of ref document: EA

ENP Entry into the national phase

Ref document number: 2004261264

Country of ref document: AU

Date of ref document: 20040729

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004261264

Country of ref document: AU

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0418618

Country of ref document: BR

Kind code of ref document: A2

Free format text: INTERESSADO: O DEPOSITANTE. DESPACHO: PEDIDO CONSIDERADO RETIRADO EM RELACAO AO BRASIL POR TER SIDO INTEMPESTIVO, NOS TERMOS DO ART. 3O DA RESOLUCAO NO 254/2010, E COMBINADO COM A REGRA 49.6 DO PCT.